User profiles for Christina I. Schroeder

Christina I Schroeder

Peptide Therapeutics, Genentech, South San Francisco, CA
Verified email at gene.com
Cited by 3491

Disulfide-rich macrocyclic peptides as templates in drug design

SE Northfield, CK Wang, CI Schroeder, T Durek… - European Journal of …, 2014 - Elsevier
Recently disulfide-rich head-to-tail cyclic peptides have attracted the interest of medicinal
chemists owing to their exceptional thermal, chemical and enzymatic stability brought about by …

[HTML][HTML] Antimicrobial peptide mimics for clinical use: does size matter?

J Svenson, N Molchanova, CI Schroeder - Frontiers in Immunology, 2022 - frontiersin.org
The search for efficient antimicrobial therapies that can alleviate suffering caused by
infections from resistant bacteria is more urgent than ever before. Infections caused by multi-…

Structure, function, and therapeutic potential of the trefoil factor family in the gastrointestinal tract

…, SM Brierley, CI Schroeder… - ACS Pharmacology & …, 2020 - ACS Publications
Trefoil factor family peptides (TFF1, TFF2, and TFF3) are key players in protecting, maintaining,
and repairing the gastrointestinal tract. Accordingly, they have the therapeutic potential to …

Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients

…, DS Nielsen, CI Schroeder… - Proceedings of the …, 2014 - National Acad Sciences
Enhancing the oral bioavailability of peptide drug leads is a major challenge in drug design.
As such, methods to address this challenge are highly sought after by the pharmaceutical …

Fmoc-based synthesis of disulfide-rich cyclic peptides

O Cheneval, CI Schroeder, T Durek… - The Journal of …, 2014 - ACS Publications
Disulfide-rich cyclic peptides have exciting potential as leads or frameworks in drug
discovery; however, their use is faced with some synthetic challenges, mainly associated with …

[HTML][HTML] ω-Conotoxin CVID inhibits a pharmacologically distinct voltage-sensitive calcium channel associated with transmitter release from preganglionic nerve …

DJ Adams, AB Smith, CI Schroeder, T Yasuda… - Journal of biological …, 2003 - ASBMB
Neurotransmitter release from preganglionic parasympathetic neurons is resistant to inhibition
by selective antagonists of L-, N-, P/Q-, R-, and T-type calcium channels. In this study, the …

[HTML][HTML] Semienzymatic cyclization of disulfide-rich peptides using Sortase A

…, KJ Rosengren, JP Mulvenna, CI Schroeder… - Journal of biological …, 2014 - ASBMB
Disulfide-rich cyclic peptides have generated great interest in the development of peptide-based
therapeutics due to their exceptional stability toward chemical, enzymatic, or thermal …

[HTML][HTML] Ant venoms contain vertebrate-selective pain-causing sodium channel toxins

…, A Keramidas, A Mueller, CI Schroeder… - Nature …, 2023 - nature.com
Stings of certain ant species (Hymenoptera: Formicidae) can cause intense, long-lasting
nociception. Here we show that the major contributors to these symptoms are venom peptides …

[HTML][HTML] Interaction of tarantula venom peptide ProTx-II with lipid membranes is a prerequisite for its inhibition of human voltage-gated sodium channel NaV1. 7

…, AE Mark, I Vetter, DJ Craik, CI Schroeder - Journal of Biological …, 2016 - ASBMB
ProTx-II is a disulfide-rich peptide toxin from tarantula venom able to inhibit the human
voltage-gated sodium channel 1.7 (hNa V 1.7), a channel reported to be involved in nociception, …

[PDF][PDF] Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro

CI Schroeder, JE Swedberg, JM Withka… - Chemistry & biology, 2014 - cell.com
Disrupting the binding interaction between proprotein convertase (PCSK9) and the epidermal
growth factor-like domain A (EGF-A domain) in the low-density lipoprotein receptor (LDL-R…